Patents by Inventor Giovanni Di Pasquale
Giovanni Di Pasquale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230181763Abstract: Provided are methods of transducing hair cells of the inner ear in a subject comprising administering to the subject an adeno-associated viral (AAV) vector comprising a nucleic acid sequence encoding a capsid comprising the amino acid sequence of SEQ ID NO: 1, wherein the AAV vector further comprises a heterologous nucleic acid sequence. Additionally, methods of treating, preventing, or inhibiting a cochlear disorder or balance disorder in a subject comprising administering the AAV vector to the subject are provided.Type: ApplicationFiled: April 30, 2021Publication date: June 15, 2023Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, Consiglio Nazionale Delle RicercheInventors: John A. Chiorini, Giovanni Di Pasquale, Fabio Mammano, Veronica Zorzi
-
Patent number: 11447797Abstract: The invention provides an adeno-associated viral (AAV) vector comprising a capsid comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 9, wherein the AAV vector further comprises a heterologous nucleic acid sequence, and wherein the heterologous nucleic acid sequence can encode the NGF-PTH fusion polypeptide or methylmalonyl CoA mutase enzyme. The invention also provides a polypeptide comprising nerve growth factor (NGF) signal peptide and parathyroid hormone (PTH), wherein the polypeptide can comprise, consist essentially of, or consist of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2. The invention provides a nucleic acid encoding the polypeptide, a vector comprising the nucleic acid, and a composition comprising the polypeptide, nucleic acid, or vector, as well as treatment methods comprising the polypeptide, nucleic acid, vector, or composition.Type: GrantFiled: May 12, 2016Date of Patent: September 20, 2022Assignee: The United States of America,as represented by the Secretary, Department of Health and Human ServiceInventors: John A. Chiorini, Giovanni Di Pasquale, Randy Chandler, Charles P. Venditti
-
AAV ISOLATE AND FUSION PROTEIN COMPRISING NERVE GROWTH FACTOR SIGNAL PEPTIDE AND PARATHYROID HORMONE
Publication number: 20180355376Abstract: The invention provides an adeno-associated viral (AAV) vector comprising a capsid comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 9, wherein the AAV vector further comprises a heterologous nucleic acid sequence, and wherein the heterologous nucleic acid sequence can encode the NGF-PTH fusion polypeptide or methylmalonyl CoA mutase enzyme. The invention also provides a polypeptide comprising nerve growth factor (NGF) signal peptide and parathyroid hormone (PTH), wherein the polypeptide can comprise, consist essentially of, or consist of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2. The invention provides a nucleic acid encoding the polypeptide, a vector comprising the nucleic acid, and a composition comprising the polypeptide, nucleic acid, or vector, as well as treatment methods comprising the polypeptide, nucleic acid, vector, or composition.Type: ApplicationFiled: May 12, 2016Publication date: December 13, 2018Applicant: The United States of America,as represented by the Secretary, Department of Health and Human ServiceInventors: John A. Chiorini, Giovanni Di Pasquale -
AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
Patent number: 9511103Abstract: The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an AAV virion comprising an AAV vector that encodes an exendin-4 protein. Also provided are exendin-4 proteins and nucleic acid molecules that encode such exendin-4 proteins. Also provided are AAV vectors and AAV virions that encode an exendin-4 protein. One embodiment is an exendin-4 protein that is a fusion protein comprising an NGF secretory segment joined to the amino terminus of an exendin-4 protein domain.Type: GrantFiled: April 19, 2012Date of Patent: December 6, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: John A. Chiorini, Giovanni Di Pasquale, Edoardo Mannucci -
Patent number: 9193769Abstract: The present invention provides a bovine adeno-associated virus (BAAV) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the BAAV vectors and particles.Type: GrantFiled: February 13, 2014Date of Patent: November 24, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: John A. Chiorini, Michael Schmidt, Ioannis Bossis, Giovanni Di Pasquale
-
Publication number: 20140221636Abstract: The present invention provides a bovine adeno-associated virus (BAAV) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the BAAV vectors and particles.Type: ApplicationFiled: February 13, 2014Publication date: August 7, 2014Applicant: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: John A. Chiorini, Michael Schmidt, Ioannis Bossis, Giovanni Di Pasquale
-
AAV MEDIATED EXENDIN-4 GENE TRANSFER TO SALIVARY GLANDS TO PROTECT SUBJECTS FROM DIABETES OR OBESITY
Publication number: 20140199272Abstract: The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an AAV virion comprising an AAV vector that encodes an exendin-4 protein. Also provided are exendin-4 proteins and nucleic acid molecules that encode such exendin-4 proteins. Also provided are AAV vectors and AAV virions that encode an exendin-4 protein. One embodiment is an exendin-4 protein that is a fusion protein comprising an NGF secretory segment joined to the amino terminus of an exendin-4 protein domain.Type: ApplicationFiled: April 19, 2012Publication date: July 17, 2014Applicants: Health and Human ServicesInventors: John A. Chiorini, Giovanni Di Pasquale, Edoardo Mannucci -
Patent number: 8685722Abstract: The present invention provides a bovine adeno-associated virus (BAAV) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the BAAV vectors and particles.Type: GrantFiled: March 6, 2012Date of Patent: April 1, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: John A. Chiorini, Michael Schmidt, Ioannis Bossis, Giovanni Di Pasquale
-
Publication number: 20140088175Abstract: The present invention provides methods of transcytosing barrier epithelial cells using adeno-associated virus-4 (AAV4), adeno-associated virus-5 (AAV5), adeno-associated virus-7 (AAV7), bovine adeno-associated virus (BAAV), and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid across the barrier epithelia using the AAV4, AAV5, AAV7, and BAAV vectors and particles.Type: ApplicationFiled: March 9, 2012Publication date: March 27, 2014Applicant: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: John A. Chiorini, Giovanni Di Pasquale
-
Publication number: 20120253018Abstract: The present invention provides a bovine adeno-associated virus (BAAV) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the BAAV vectors and particles.Type: ApplicationFiled: March 6, 2012Publication date: October 4, 2012Applicants: Human ServicesInventors: John A. Chiorini, Michael Schmidt, Ioannis Bossis, Giovanni Di Pasquale
-
Publication number: 20080188431Abstract: The present invention provides methods of transcytosing barrier epithelial cells using adeno-associated virus-4 (AAV4), adeno-associated virus-5 (AAV5), adeno-associated virus-7 (AAV7), bovine adeno-associated virus (BAAV), and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid across the barrier epithelia using the AAV4, AAV5, AAV7, and BAAV vectors and particles.Type: ApplicationFiled: September 8, 2005Publication date: August 7, 2008Inventors: John A. Chiorini, Giovanni Di Pasquale
-
Patent number: 6983159Abstract: A TMSI, comprising a TMSI identification field and a TMSI generation field, is allocated to a mobile subscriber. For non-restart situations, this involves selecting an unused TMSI identification field value; determining an associated present TMSI generation field value; and performing a normal allocation adjustment to the present TMSI generation field value, thereby producing an adjusted TMSI generation field value. A complete TMSI is generated from the selected TMSI identification value and the adjusted TMSI generation field value. The complete TMSI is allocated to the mobile subscriber. For a normal release situation, the TMSI identification value is processed so that it will be considered unused, and a normal deallocation adjustment is performed to the adjusted TMSI generation field value. In some embodiments, the normal deallocation adjustment restores the TMSI generation field to its earlier value. In an abnormal release, the TMSI generation field value is left unchanged.Type: GrantFiled: December 18, 2001Date of Patent: January 3, 2006Assignee: Telefonaktiebolaget LM Ericsson (publ)Inventors: Gianluca Giovanni Di Pasquale, Vatche Varvarian, Arndt Ritterbecks
-
Publication number: 20020168977Abstract: A TMSI, comprising a TMSI identification field and a TMSI generation field, is allocated to a mobile subscriber,. For non-restart situations, this involves selecting an unused TMSI identification field value; determining an associated present TMSI generation field value; and performing a normal allocation adjustment to the present TMSI generation field value, thereby producing an adjusted TMSI generation field value. A complete TMSI is generated from the selected TMSI identification value and the adjusted TMSI generation field value. The complete TMSI is allocated to the mobile subscriber. For a normal release situation, the TMSI identification value is processed so that it will be considered unused, and a normal deallocation adjustment is performed to the adjusted TMSI generation field value. In some embodiments, the normal deallocation adjustment restores the TMSI generation field to its earlier value. In an abnormal release, the TMSI generation field value is left unchanged.Type: ApplicationFiled: December 18, 2001Publication date: November 14, 2002Inventors: Gianluca Giovanni Di Pasquale, Vatche Varvarian, Arndt Ritterbecks